Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.

Louisa SchererMarc SoudantSophie Pittion-VouyovitchMarc DebouverieFrancis GuilleminJonathan EpsteinGuillaume Mathey

Published in: Journal of neurology (2024)

the risk of conversion to secondary progression associated with natalizumab treatment is relatively low but increases in case of natalizumab discontinuation in the absence of switch to highly active immunosuppressant.

Keyphrases

multiple sclerosis
white matter
combination therapy
newly diagnosed
replacement therapy